Analyzing generic and branded substitution patterns in the Netherlands using prescription data
- PMID: 21524312
- PMCID: PMC3107776
- DOI: 10.1186/1472-6963-11-89
Analyzing generic and branded substitution patterns in the Netherlands using prescription data
Abstract
Background: As in other societies, pharmaceutical expenditures in the Netherlands are rising every year. As a consequence, needs for cost control are often expressed. One possible solution for cost control could come through increasing generic substitution by pharmacists. We aim to analyse the extent and nature of substitution in recent years and estimate the likelihood of generic or branded substitution in Dutch pharmacies in relation to various characteristics.
Methods: We utilized a linked prescription dataset originating from a general practitioner (GP) and a pharmacy database, both from the northern Netherlands. We selected specific drugs of interest, containing about 55,000 prescriptions from 15 different classes. We used a crossed generalized linear mixed model to estimate the effects that certain patient and pharmacy characteristics as well as timing have on the likelihood that a prescription will eventually be substituted by the pharmacist.
Results: Generic substitution occurred at 25% of the branded prescriptions. Generic substitution was more likely to occur earlier in time after patent expiry and to patients that were older and more experienced in their drug use. Individually owned pharmacies had a lower probability of generic substitution compared to chain pharmacies. Oppositely, branded substitution occurred in 10% of generic prescriptions and was positively related to the patients' experience in branded use. Individually owned pharmacies were more likely to substitute a generic drug to a branded compared to other pharmacies. Antidepressant and PPI prescriptions were less prone to generic and more prone to branded substitution.
Conclusion: Analysis of prescription substitution by the pharmacist revealed strong relations between substitution and patient experience on drug use, pharmacy status and timing. These findings can be utilised to design further strategies to enhance generic substitution.
Figures
Similar articles
-
The changing patterns of dispensing branded and generic drugs for the treatment of gastroesophageal reflux disease between 2006 and 2011 in Japan: a retrospective cohort study.BMC Health Serv Res. 2015 Feb 27;15:76. doi: 10.1186/s12913-015-0734-2. BMC Health Serv Res. 2015. PMID: 25885571 Free PMC article.
-
A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.J Manag Care Spec Pharm. 2014 Sep;20(9):959-67. doi: 10.18553/jmcp.2014.20.9.959. J Manag Care Spec Pharm. 2014. PMID: 25166295 Free PMC article.
-
Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases.BMJ. 2019 Nov 5;367:l6015. doi: 10.1136/bmj.l6015. BMJ. 2019. PMID: 31690553 Free PMC article.
-
[The «not substitutable» using: a comparative study of general practitioners and community pharmacists' views from prescription to delivery].Therapie. 2014 Sep-Oct;69(5):401-17. doi: 10.2515/therapie/2014053. Epub 2014 Oct 1. Therapie. 2014. PMID: 25269142 French.
-
Evergreened drugs or evergreened profits?J Eval Clin Pract. 2022 Dec;28(6):1119-1126. doi: 10.1111/jep.13695. Epub 2022 May 11. J Eval Clin Pract. 2022. PMID: 35543377 Review.
Cited by
-
Drug switching in the Netherlands: a cohort study of 20 active substances.BMC Health Serv Res. 2020 Jul 13;20(1):650. doi: 10.1186/s12913-020-05494-x. BMC Health Serv Res. 2020. PMID: 32660480 Free PMC article.
-
A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.BMC Health Serv Res. 2013 Oct 5;13:390. doi: 10.1186/1472-6963-13-390. BMC Health Serv Res. 2013. PMID: 24093493 Free PMC article.
-
Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.Rheumatol Int. 2021 Jan;41(1):163-171. doi: 10.1007/s00296-020-04576-7. Epub 2020 Apr 16. Rheumatol Int. 2021. PMID: 32300866
-
The diffusion of generics after patent expiry in Germany.Eur J Health Econ. 2016 Nov;17(8):1027-1040. doi: 10.1007/s10198-015-0744-3. Epub 2015 Nov 16. Eur J Health Econ. 2016. PMID: 26573841
-
Policies and Practices Catalyzing the Use of Generic Medicines: A Systematic Search and Review.Ethiop J Health Sci. 2021 Jan;31(1):167-178. doi: 10.4314/ejhs.v31i1.19. Ethiop J Health Sci. 2021. PMID: 34158764 Free PMC article. Review.
References
-
- Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21(Pt 2):89–103. - PubMed
-
- Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Plann Manage. 2005;20(Pt 4):291–306. - PubMed
-
- Steering Committee on Future Health Scenarios. The Future of Medicines in Health Care: Scenario Report. New York: Springer; 1995.
-
- Perry G. The European generic pharmaceutical market in review: 2006 and beyond. Journal of Generic Medicines. 2006;4:4–14. doi: 10.1057/palgrave.jgm.4950041. - DOI
-
- Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health policy. 2000;51(Pt 3):149–162. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials